Clinical Trial Update: Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics study of lemborexant and its metabolites in subjects with hepatic impairment versus healthy controls completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatic Impairment

Drugs mentioned

• Lemborexant (lemborexant)

Snippet

Sponsor: Eisai Inc. | Conditions: Hepatic Impairment | Phase 1 | Status: COMPLETED | Results posted: 2020-01-18